You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 265 No. 22, June 12, 1991 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis

T. J. Jordan, E. M. Lewit, R. L. Montgomery and L. B. Reichman
Division of Informatics, University of Medicine & Dentistry of New Jersey, New Jersey Medical School, Newark 07103-2406.

Tuberculin skin testing is a notoriously poor marker of tuberculosis infection in patients who are serologically positive for the human immunodeficiency virus. A decision analysis was performed to determine if and when isoniazid should be prescribed to prevent tuberculosis in these patients. The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied. The assumptions and parameter estimates selected for this investigation represent a highly conservative vantage point opposing the use of isoniazid as a preventive therapy. Nevertheless, results showed a benefit from the use of isoniazid as a preventive therapy for all groups, even without tuberculin testing, except tuberculin-negative black women. This benefit of isoniazid therapy increased patient life expectancy as much as 285 days. Further, the decisions continue to favor prescribing isoniazid even when the suspected incidence of tuberculosis infection falls as low as 3% to 8%. Tuberculin testing appears important primarily for black women, since those who have negative tuberculin skin tests may not be candidates for isoniazid therapy.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of Rifampin
Lardizabal et al.
Chest 2006;130:1712-1717.
ABSTRACT | FULL TEXT  

Considering the Role of Four Months of Rifampin in the Treatment of Latent Tuberculosis Infection
Reichman et al.
Am. J. Respir. Crit. Care Med. 2004;170:832-835.
FULL TEXT  

Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months
Menzies et al.
Am. J. Respir. Crit. Care Med. 2004;170:445-449.
ABSTRACT | FULL TEXT  

Tuberculosis Prevention in Methadone Maintenance Clinics . Effectiveness and Cost-Effectiveness
SNYDER et al.
Am. J. Respir. Crit. Care Med. 1999;160:178-185.
ABSTRACT | FULL TEXT  

Preventive Therapy for Tuberculosis in HIV-Infected Persons: Analysis of Policy Options Based on Tuberculin Status and CD4+Cell Count
Sawert et al.
Arch Intern Med 1998;158:2112-2121.
ABSTRACT | FULL TEXT  

Skin Anergy Testing and Tuberculosis Surveillance
Lincoln et al.
JOURNAL OF CORRECTIONAL HEALTH CARE 1997;4:139-153.
ABSTRACT  

Tuberculosis, AIDS, and Death among Substance Abusers on Welfare in New York City
Friedman et al.
NEJM 1996;334:828-833.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.